Compare Stocks: JNJ, PTGX, and KVUE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$270.99 -1.5%	$262.32	$173.33 ▼ $281.07	$650.97B	0.24	8.11 million shs	3.59 million shs
KVUE Kenvue	$18.51 -1.3%	$19.18	$14.02 ▼ $20.13	$35.51B	0.46	27.67 million shs	8.58 million shs
PTGX Protagonist Therapeutics	$147.09 +0.9%	$141.67	$54.50 ▼ $160.81	$9.52B	1.8	706,875 shs	196,025 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	0.00%	+3.51%	+6.21%	+16.14%	+54.39%
KVUE Kenvue	0.00%	-1.06%	-2.72%	+4.44%	+0.35%
PTGX Protagonist Therapeutics	0.00%	-1.37%	-0.10%	+37.64%	+140.74%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$270.99 -1.5%	$262.32	$173.33 ▼ $281.07	$650.97B	0.24	8.11 million shs	3.59 million shs
KVUE Kenvue	$18.51 -1.3%	$19.18	$14.02 ▼ $20.13	$35.51B	0.46	27.67 million shs	8.58 million shs
PTGX Protagonist Therapeutics	$147.09 +0.9%	$141.67	$54.50 ▼ $160.81	$9.52B	1.8	706,875 shs	196,025 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	0.00%	+3.51%	+6.21%	+16.14%	+54.39%
KVUE Kenvue	0.00%	-1.06%	-2.72%	+4.44%	+0.35%
PTGX Protagonist Therapeutics	0.00%	-1.37%	-0.10%	+37.64%	+140.74%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JNJ Johnson & Johnson	2.80	Moderate Buy	$272.83	0.68% Upside
KVUE Kenvue	2.20	Hold	$19.27	4.15% Upside
PTGX Protagonist Therapeutics	2.89	Moderate Buy	$147.13	0.03% Upside

Current Analyst Ratings Breakdown

Latest JNJ, PTGX, and KVUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	JNJ Johnson & Johnson	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$280.00 ➝ $320.00
9/1/2026	PTGX Protagonist Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$153.00 ➝ $180.00
9/1/2026	PTGX Protagonist Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$178.00 ➝ $190.00
8/31/2026	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$175.00 ➝ $182.00
8/31/2026	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/31/2026	PTGX Protagonist Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/31/2026	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$167.00 ➝ $170.00
8/17/2026	PTGX Protagonist Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$112.00 ➝ $178.00
8/11/2026	PTGX Protagonist Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C+)
8/11/2026	KVUE Kenvue	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$20.00 ➝ $19.00
8/10/2026	PTGX Protagonist Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$145.00 ➝ $170.00

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JNJ Johnson & Johnson	$94.19B	6.93	$13.90 per share	19.49	$33.85 per share	8.01
KVUE Kenvue	$15.41B	2.31	$1.36 per share	13.59	$5.62 per share	3.29
PTGX Protagonist Therapeutics	$46.02M	206.82	N/A	N/A	$9.83 per share	14.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JNJ Johnson & Johnson	$26.80B	$8.63	31.30	21.17	2.63	21.48%	32.42%	13.35%	10/13/2026 (Estimated)
KVUE Kenvue	$1.47B	$0.87	21.25	15.04	1.67	10.76%	21.22%	8.37%	11/2/2026 (Estimated)
PTGX Protagonist Therapeutics	-$130.15M	$1.03	142.80	N/A	N/A	29.40%	12.03%	11.23%	11/5/2026 (Estimated)

Latest JNJ, PTGX, and KVUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	KVUE Kenvue	$0.3187	$0.31	-$0.0087	$0.24	$3.97 billion	$3.96 billion
8/5/2026	Q2 2026	PTGX Protagonist Therapeutics	$2.27	$2.29	+$0.02	$2.29	$212.03 million	$213.48 million
7/15/2026	Q2 2026	JNJ Johnson & Johnson	$2.84	$2.90	+$0.06	$2.27	$25.06 billion	$25.31 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
JNJ Johnson & Johnson	$5.36	1.98%	+5.25%	62.11%	64 Years
KVUE Kenvue	$0.84	4.54%	N/A	96.55%	1 Years
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest JNJ, PTGX, and KVUE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/15/2026	JNJ Johnson & Johnson	quarterly	$1.34	1.96%	8/25/2026	8/25/2026	9/8/2026
7/29/2026	KVUE Kenvue	quarterly	$0.21	4.43%	8/12/2026	8/12/2026	8/26/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JNJ Johnson & Johnson	0.44	1.09	0.81
KVUE Kenvue	0.67	1.01	0.71
PTGX Protagonist Therapeutics	N/A	21.71	21.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JNJ Johnson & Johnson	69.55%
KVUE Kenvue	97.64%
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
JNJ Johnson & Johnson	0.16%
KVUE Kenvue	1.59%
PTGX Protagonist Therapeutics	5.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.41 billion	Optionable
KVUE Kenvue	22,000	1.92 billion	1.89 billion	Optionable
PTGX Protagonist Therapeutics	120	64.71 million	61.35 million	Optionable

JNJ, PTGX, and KVUE Headlines

Recent News About These Companies

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 7 at 2:13 AM | marketbeat.com

Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status

September 6 at 11:31 AM | insidermonkey.com

MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?

September 4, 2026 | finance.yahoo.com

Q1 Earnings Estimate for PTGX Issued By HC Wainwright

September 4, 2026 | americanbankingnews.com

BMO Capital Markets Boosts Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $190.00

September 3, 2026 | americanbankingnews.com

Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)

September 2, 2026 | theglobeandmail.com

Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Protagonist Therapeutics (PTGX)

September 2, 2026 | theglobeandmail.com

Research Analysts Offer Predictions for PTGX Q1 Earnings

September 2, 2026 | marketbeat.com

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026

September 2, 2026 | accessnewswire.comA

Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News

September 2, 2026 | uk.finance.yahoo.com

The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones

September 1, 2026 | finance.yahoo.com

Protagonist Therapeutics (NASDAQ:PTGX) Given New $190.00 Price Target at BMO Capital Markets

September 1, 2026 | marketbeat.com

Why Is Protagonist Therapeutics (PTGX) In Focus After MIMRYLO FDA Approval?

September 1, 2026 | uk.finance.yahoo.com

Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says

August 31, 2026 | finance.yahoo.com

Protagonist Therapeutics' Mimrylo Holds Commercial Potential After FDA Approval, Truist Says

August 31, 2026 | finance.yahoo.com

Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript

August 31, 2026 | seekingalpha.com

Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment

August 31, 2026 | marketbeat.com

Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera - Slideshow

August 31, 2026 | seekingalpha.com

132,351 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Legal & General Group Plc

August 31, 2026 | marketbeat.com

Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.

August 31, 2026 | fool.com

Wellington Management Group LLP Sells 182,863 Shares of Protagonist Therapeutics, Inc. $PTGX

August 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

JNJ, PTGX, and KVUE Company Descriptions

Johnson & Johnson NYSE:JNJ

$270.99 -4.24 (-1.54%)

As of 02:09 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Kenvue NYSE:KVUE

$18.50 -0.24 (-1.25%)

As of 02:09 PM Eastern

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

Protagonist Therapeutics NASDAQ:PTGX

$147.08 +1.37 (+0.94%)

As of 02:09 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JNJ, PTGX, and KVUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JNJ, PTGX, and KVUE Earnings

Compare Dividends

Latest JNJ, PTGX, and KVUE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JNJ, PTGX, and KVUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

JNJ, PTGX, and KVUE Company Descriptions

Johnson & Johnson NYSE:JNJ

Kenvue NYSE:KVUE

Protagonist Therapeutics NASDAQ:PTGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JNJ, PTGX, and KVUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JNJ, PTGX, and KVUE Earnings

Compare Dividends

Latest JNJ, PTGX, and KVUE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JNJ, PTGX, and KVUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

JNJ, PTGX, and KVUE Company Descriptions

Johnson & Johnson NYSE:JNJ

Kenvue NYSE:KVUE

Protagonist Therapeutics NASDAQ:PTGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools